Ann Vasc Dis. 2024 Dec 25;17(4):467-487. doi: 10.3400/avd.ar.24-00052. Epub 2024 Sep 18.
This is an annual report indicating the number and early clinical results of annual vascular treatment performed by vascular surgeons in Japan in 2018, as analyzed by database management committee (DBC) members of the Japanese Society for Vascular Surgery (JSVS). To survey the current status of vascular treatments performed by vascular surgeons in Japan, the DBC members of the JSVS analyzed the vascular treatment data provided by the National Clinical Database (NCD), including the number of treatments and early results such as operative and hospital mortality. In total, 143,745 vascular treatments were registered by 1,090 institutions in 2018. This database comprises seven fields, including treatment of aneurysms, chronic arterial occlusive disease, acute arterial occlusive disease, vascular injury, complication of previous vascular reconstruction, venous diseases, and other vascular treatments. The number of vascular treatments in each field was 24,495, 18,700, 4,813, 2,363, 694, 45,088, and 47,592, respectively. In the field of aneurysm treatment, 20,160 cases of abdominal aortic aneurysm (AAA), including common iliac aneurysm, were registered, and 61.6% were treated by endovascular aneurysm repair (EVAR). Among AAA cases, 1,794 (8.9%) cases were registered as ruptured AAA. The operative mortality rates of ruptured and unruptured AAA were 15.7% and 0.6%, respectively. Approximately 43.3% of ruptured AAA were treated by EVAR, and the EVAR ratio was gradually increasing, but the operative mortality rates of open repair and EVAR for ruptured AAA were 14.0% and 14.6%, respectively. Regarding chronic arterial occlusive disease, open repair was performed in 8,336 cases, including 1,348 distal bypasses to the crural or pedal artery, whereas endovascular treatment (EVT) was performed in 9,710 cases. The EVT ratio was gradually increased at 51.9%. Varicose vein treatment was decreased in 43,133 cases (7.7% less than that in 2017), and 77.3% of the cases were treated by endovenous thermal ablation (ETA), including endovenous laser ablation (EVLA) and radiofrequency ablation (RFA). Regarding other vascular operations, 44,003 cases of vascular access operations and 1,631 lower limb amputation surgeries were included. The number of vascular treatments increased since 2017, and the proportion of endovascular procedures increased in almost all fields of vascular diseases, especially EVAR for AAA, EVT for chronic arterial occlusive disease, and ETA for varicose veins. (This is a translation of Jpn J Vasc Surg 2022; 31: 217-237.).
这是一份年度报告，展示了2018年日本血管外科医生进行的年度血管治疗的数量和早期临床结果，由日本血管外科学会（JSVS）的数据库管理委员会（DBC）成员进行分析。为了调查日本血管外科医生进行血管治疗的现状，JSVS的DBC成员分析了国家临床数据库（NCD）提供的血管治疗数据，包括治疗数量以及手术和医院死亡率等早期结果。2018年，1090家机构共登记了143,745例血管治疗。该数据库涵盖七个领域，包括动脉瘤治疗、慢性动脉闭塞性疾病、急性动脉闭塞性疾病、血管损伤、既往血管重建并发症、静脉疾病以及其他血管治疗。每个领域的血管治疗数量分别为24,495例、18,700例、4,813例、2,363例、694例、45,088例和47,592例。在动脉瘤治疗领域，登记了20,160例腹主动脉瘤（AAA）病例，包括髂总动脉瘤，其中61.6%通过血管腔内动脉瘤修复术（EVAR）进行治疗。在AAA病例中，1794例（8.9%）被登记为破裂性AAA。破裂性和非破裂性AAA的手术死亡率分别为15.7%和0.6%。约43.3%的破裂性AAA通过EVAR进行治疗，EVAR比例逐渐上升，但破裂性AAA开放修复和EVAR的手术死亡率分别为14.0%和14.6%。对于慢性动脉闭塞性疾病，8336例进行了开放修复，其中包括1348例远端至小腿或足部动脉的旁路手术，而9710例进行了血管腔内治疗（EVT）。EVT比例逐渐上升至51.9%。静脉曲张治疗病例为43,133例（比2017年减少7.7%），其中77.3%的病例通过静脉内热消融（ETA）进行治疗，包括静脉内激光消融（EVLA）和射频消融（RFA）。对于其他血管手术，包括44,003例血管通路手术和1631例下肢截肢手术。自2017年以来，血管治疗数量增加，血管腔内手术的比例在几乎所有血管疾病领域都有所上升，尤其是AAA的EVAR、慢性动脉闭塞性疾病的EVT以及静脉曲张的ETA。（本文翻译自《日本血管外科学杂志》2022年；31: 217 - 237.）
